Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc.   (NYSE American:XTNT), a global medical technology company focused on

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne , CEO and Scott Neils , CFO will be attending the

BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September

BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries.

BELGRADE, MT / ACCESSWIRE / September 18, 2024 /) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and

BELGRADE, Mont. , May 13, 2024 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after

BELGRADE, Mont. , April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts,

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont. , April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported